Objective
to assess whether 1-month prasugrel-based DAPT followed by low-dose prasugrel monotherapy is as safe and effective as standard 12-month prasugrel-based DAPT in ACS patients treated with a polymer-free drug-coated stent
Study
multicentre, randomised, open-label, non-inferiority trial
Population
ACS patients undergoing PCI with drug-coated stents (DCS)
Endpoints
net adverse clinical events (all-cause death, non-fatal MI, stroke, ischaemia-driven TVR, and BARC type 2-5 bleeding) at 12 months
Conclusion
One-month DAPT followed by prasugrel 5 mg monotherapy reduced NACE by 49%, primarily driven by a 77% reduction in bleeding without increasing ischaemic events, when compared to 12-month DAPT.
Jang et al. EuroIntervention. 2025 Jul 21.